Gastrointestinal Motility Evidence: Moderate (animal data strong, human data mixed) This benefit surprised researchers
There are three GLP-1 FDA decisions expected in 2025, all for Novo Nordisks semaglutide: Ozempic for T2DM and peripheral artery disease (PAD) Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity The first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape
Nikitin D, Lin GA, Campbell JD, Hansen RN, Brouwer E, Chen Y, et al
As part of a balanced routine-healthy meals, regular activity, and enough sleep-it may help support appetite balance and long-term weight management
Through its interaction with actin, Thymosin Beta 4 facilitates cellular movements and orchestrates the repair of damaged tissues, making it a promising therapeutic agent for various conditions
